Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy.
about
Pharmacology of manipulating lean body massRescue of dystrophic skeletal muscle by PGC-1α involves a fast to slow fiber type shift in the mdx mouseEvaluation of Electrical Impedance as a Biomarker of Myostatin Inhibition in Wild Type and Muscular Dystrophy MiceBlockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy.Administration of a soluble activin type IIB receptor promotes the transplantation of human myoblasts in dystrophic miceA proteasome inhibitor fails to attenuate dystrophic pathology in mdx mice.Supraphysiological levels of GDF11 induce striated muscle atrophyGene expression profiling of skeletal muscles treated with a soluble activin type IIB receptorCurrent status of pharmaceutical and genetic therapeutic approaches to treat DMD.Role of TGF-β signaling in inherited and acquired myopathies.Long-term systemic myostatin inhibition via liver-targeted gene transfer in golden retriever muscular dystrophy.Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy.Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular AtrophyLong-term wheel running compromises diaphragm function but improves cardiac and plantarflexor function in the mdx mouseNew function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration.Circulating Biomarkers for Duchenne Muscular Dystrophy.Denervation atrophy is independent from Akt and mTOR activation and is not rescued by myostatin inhibitionCell-matrix interactions in muscle disease.Cytokines and chemokines as regulators of skeletal muscle inflammation: presenting the case of Duchenne muscular dystrophy.Prospect for pharmacological therapies to treat skeletal muscle dysfunction.Rescue of dystrophic skeletal muscle by PGC-1α involves restored expression of dystrophin-associated protein complex components and satellite cell signaling.ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.Muscle protein synthesis, mTORC1/MAPK/Hippo signaling, and capillary density are altered by blocking of myostatin and activins.Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne.Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.Genetic modifiers of Duchenne and facioscapulohumeral muscular dystrophies.Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.Genetic disruption of Smad7 impairs skeletal muscle growth and regeneration.Discovery of biological networks using an optimized partial correlation coefficient with information theory algorithm on Stampede's Xeon and Xeon Phi processorsMyostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone
P2860
Q26824503-2BE88F7F-D5BA-4F62-8457-1D33803CA084Q27310125-555873C0-0CE6-4DA5-B9F3-B9CBCA70CB3CQ28550406-977F14B1-C32C-4324-9CD2-49A1D386B08CQ30650948-92F6834C-5B81-498A-91D8-0B922D41E4F6Q33881904-C18F5DAB-69EF-45F5-90F3-A6039D6EAF08Q34367192-49CCD224-F9BE-4366-8DDA-33B8484BD093Q34552864-21B5B7C2-E3EF-4A0E-9650-413C2D108EE7Q34973594-63918563-3C9E-4926-BC35-608BE5A6ED19Q34994545-8CAC051B-44CF-48FD-8BEE-EA100B246C44Q35166254-B9C93A15-FEED-4DD9-9B8E-2915401C656AQ35612576-998CEDCD-43D6-4594-89AF-37D316AB389DQ36089367-18A99811-FF97-4764-B0FD-B523105A6487Q36199822-48E2AD12-83DE-4731-8E53-CE5C7E4F2FF5Q37147219-3022203E-56CA-4A70-9E7A-FF32B1D4BAF8Q37510390-415E8E3F-9EED-4B54-92D3-D6EFFBCFD0A5Q37610530-287ADE91-00E3-4D08-9057-4275B61B7CA3Q37682385-66235CE0-DAD1-41C1-9839-B0D6E6182E94Q37944530-9D9CFFDB-0B19-4B9A-A42C-4800109E7835Q38168509-D1E25744-90F3-481D-A4F3-29329B80CA03Q38264369-3AAB0559-3A78-47B8-888E-C100A52A16DEQ45080100-83B50ED2-0946-4395-A805-CC14F8CCE7D0Q45219853-CEEA0034-BFB6-446F-874D-A73E13ACAE96Q46401273-9C7B7DF6-26A8-4438-A74A-5F42EC1F2989Q47115483-60BE0482-53C9-4345-9330-6181F69B004DQ47303605-F19ED190-96B0-47BB-9EC9-939A6ED8F9A2Q47337769-E64ED9AC-A946-47AC-ABA4-E81029D0BA77Q50973442-53D36A39-2E19-4CB8-9B3D-B76F92AE1C6BQ51613530-05503B9F-BE38-4B06-97CD-EBDDC97173C8Q52658995-9BDCAE8D-97CF-4CBF-9D49-803FA4BE6DC0Q57539934-597286CA-DE0B-4BC9-8321-8E60750F29DDQ58112184-5803D0C0-A0F9-46E6-B47B-BBF7186B8564
P2860
Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Activin IIB receptor blockade ...... f Duchenne muscular dystrophy.
@en
Activin IIB receptor blockade ...... f Duchenne muscular dystrophy.
@nl
type
label
Activin IIB receptor blockade ...... f Duchenne muscular dystrophy.
@en
Activin IIB receptor blockade ...... f Duchenne muscular dystrophy.
@nl
prefLabel
Activin IIB receptor blockade ...... f Duchenne muscular dystrophy.
@en
Activin IIB receptor blockade ...... f Duchenne muscular dystrophy.
@nl
P2093
P2860
P356
P1433
P1476
Activin IIB receptor blockade ...... of Duchenne muscular dystrophy
@en
P2093
Elisabeth R Barton
H Lee Sweeney
Jeffery A Gazzara
Kevin J Morine
Klara Pendrak
Lawrence T Bish
Meg M Sleeper
Se-Jin Lee
P2860
P304
P356
10.1002/MUS.21743
P577
2010-11-01T00:00:00Z